Cabergoline

Generic Name: Cabergoline

Brand Names: Dostinex

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇N_₅O_₂

CAS Number: 81409-90-7

Unique Ingredient Identifier: LL60K9J05T

Background: Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Indication: For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.

Associated Conditions: Hyperprolactinemia, Idiopathic hyperprolactinemic disorder

Associated Therapies: Inhibition of physiological lactation

Clinical Trials

The Influence of Timing of Cabergoline Initiation on Prevention of OHSS

Phase 3

Conditions: Ovarian Hyperstimulation Syndrome

Interventions: Drug: Late Cabergoline 0.5mg
Drug: Early Cabergoline 0.5mg

First Posted Date: 2015-12-03

Last Posted Date: 2018-04-10

Lead Sponsor: Mona M Shaban

Target Recruit Count: 75

Registration Number: NCT02620605

Locations: 🇪🇬
IVF department in Kasr Alaini hospital,private IVF centre, Cairo, Egypt

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: Norethindrone acetate
Drug: Cabergoline

First Posted Date: 2015-09-07

Last Posted Date: 2020-02-05

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 10

Registration Number: NCT02542410

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Conditions: OHSS

Interventions: Drug: GnRH antagonist rescue & cabergoline
Drug: Cabergoline

First Posted Date: 2015-06-03

Last Posted Date: 2015-11-17

Lead Sponsor: Aljazeera Hospital

Target Recruit Count: 236

Registration Number: NCT02461875

Locations: 🇪🇬
Aljazeera( Al Gazeera) hospital, Giza, Egypt

Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection

Phase 2

Conditions: Infertility

Interventions: Drug: Cabergoline

First Posted Date: 2014-12-03

Last Posted Date: 2016-12-06

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 150

Registration Number: NCT02306564

Locations: 🇪🇬
Assissted reproduction unit Kasr alaini hospital, Garden city, Cairo, Egypt

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

Phase 3

Recruiting

Conditions: Pituitary Neoplasms
Adenoma

Interventions: Drug: cabergoline

First Posted Date: 2014-11-13

Last Posted Date: 2024-06-04

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 60

Registration Number: NCT02288962

Locations: 🇳🇴
Department of Endocrinology, Akershus University hospital, Oslo, Norway
🇸🇪
Sahlgrenska University Hospital, Gøteborg, Sweden
🇳🇴
Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway

Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Calcium Dobesilate
Drug: Cabergoline

First Posted Date: 2014-10-22

Last Posted Date: 2017-02-16

Lead Sponsor: Benha University

Target Recruit Count: 200

Registration Number: NCT02271360

Locations: 🇪🇬
Benha univesity hospital, Benha, El Qualyobia, Egypt

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Diosmin
Drug: Cabergoline

First Posted Date: 2014-05-09

Last Posted Date: 2016-02-02

Lead Sponsor: Benha University

Target Recruit Count: 200

Registration Number: NCT02134249

Locations: 🇪🇬
Benha univesity hospital, Benha, El Qualyobia, Egypt
🇪🇬
Banha Universty, Banha, El Qalubia, Egypt

Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

Phase 4

Completed

Conditions: Adverse Reaction to Other Drugs and Medicines

Interventions: Drug: cabergoline treatment

First Posted Date: 2013-10-08

Last Posted Date: 2013-10-08

Lead Sponsor: Istanbul Bakirkoy Maternity and Children Diseases Hospital

Target Recruit Count: 48

Registration Number: NCT01957839

Locations: 🇹🇷
Sisli Etfal Teaching Hosital, Sisli, Turkey

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4

Completed

Conditions: Acromegaly
Pituitary Tumors
Ectopic ACTH Secreting (EAS) Tumors
Melanoma Negative for bRAF
Cushing's Disease
Neuroendocrine Tumors
Prostate Cancer
Melanoma Negative for nRAS
Dumping Syndrome

Interventions: Drug: Pasireotide
Drug: Pasireotide LAR
Drug: Cabergoline

First Posted Date: 2013-02-20

Last Posted Date: 2024-10-01

Lead Sponsor: RECORDATI GROUP

Target Recruit Count: 337

Registration Number: NCT01794793

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States
🇮🇹
Milano Investigative Site, Milano, MI, Italy
🇺🇸
Ximed Research SC - SOM230B2412, La Jolla, California, United States

and more 6 locations

Cabergoline in Metastatic Breast Cancer

Early Phase 1

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: cabergoline

First Posted Date: 2012-11-21

Last Posted Date: 2019-09-17

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT01730729

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy